Seattle Genetics Trial Fills Up

Luke Timmerman8/24/09

Seattle Genetics, the Bothell, WA-based developer of cancer drugs, said today that it has completed enrollment in the pivotal clinical trial of its lead product candidate, brentuxmab vedotin (SGN-35). The trial recruited 100 patients with relapsed forms of Hodgkin’s disease. The enrollment period was about six months faster than the company expected, so Seattle Genetics expects to have results from the trial sooner as well, by the second half of 2010. The speed of the enrollment helped Seattle Genetics raise $136 million in a stock offering, as we described in this recent feature story.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.